Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1156 to 1170 of 1363 results for social care

  1. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  2. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued Reference number: GID-TA10634

    Technology appraisal guidance
    Discontinued

  3. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued Reference number: GID-TA10320

    Technology appraisal guidance
    Discontinued

  4. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  5. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

    Technology appraisal guidance
    Discontinued

  6. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued Reference number: GID-TA10668

    Technology appraisal guidance
    Discontinued

  8. Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

    Discontinued Reference number: GID-TA10625

    Technology appraisal guidance
    Discontinued

  9. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued Reference number: GID-TA10857

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued Reference number: GID-TA10929

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued Reference number: GID-TA10228

    Technology appraisal guidance
    Discontinued

  12. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  13. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued Reference number: GID-TA10492

    Technology appraisal guidance
    Discontinued

  14. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued Reference number: GID-TA10635

    Technology appraisal guidance
    Discontinued

  15. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued Reference number: GID-TA10308

    Technology appraisal guidance
    Discontinued